Estradiol

Generic Name: Estradiol

Brand Names: Activella 1/0.5 28 Day, Activelle, Amabelz 0.5/0.1 28 Day, Angeliq 0.25/0.5 28 Day, Bijuva, Climara, Climara Pro, Combipatch, Divigel, Dotti, Elestrin, Estalis, Estrace, Estradot, Estring, Estrogel, Etyqa 0.5/0.1 28 Day, Evamist, Imvexxy 4 Mcg Starter Pack, Lopreeza 1/0.5 28 Day, Lyllana, Menostar, Mimvey, Minivelle, Myfembree, Oesclim, Oriahnn 28 Day Kit, Prefest 30 Day, Vagifem, Vivelle, Yuvafem

Drug Type: Small Molecule

Chemical Formula: C_₁₈H_₂₄O_₂

CAS Number: 50-28-2

Unique Ingredient Identifier: 4TI98Z838E

Background: Estradiol is a naturally occurring hormone circulating endogenously in females. It is commercially available in several hormone therapy products for managing conditions associated with reduced estrogen, such as vulvovaginal atrophy and hot flashes. Some available forms of estradiol include oral tablets, injections, vaginal rings, transdermal patches, sprays,...

Indication: Estradiol is indicated in various preparations for the treatment of moderate to severe vasomotor symptoms and vulvar and vaginal atrophy due to menopause, for the treatment of hypoestrogenism due to hypogonadism, castration, or primary ovarian failure, and for the prevention of postmenopausal osteoporosis. It is also used for the treatment of breast cancer (...

Associated Conditions: Atrophic Vaginitis, Breast Cancer, Breast engorgement caused by Postpartum state, Heavy Menstrual Bleeding, Hypogonadism female, Kraurosis Vulvae, Metastatic Breast Cancer, Osteoporosis, Postmenopausal Osteoporosis, Premature Ovarian Failure (POF), Prostate Cancer, Severe Pain, Urogenital atrophy, Vasomotor Symptoms Associated With Menopause, Vulvo Vaginal Atrophy, Advanced androgen dependent Prostate cancer, Female castration, Hypoestrogenism

Associated Therapies: Contraception, Hormone Replacement Therapy, Palliative Treatment

Clinical Trials

A Study Comparing Estradiol Vaginal Cream to Estrace® Cream in Females With Atrophic Vaginitis

Phase 3

Completed

Conditions: Atrophic Vaginitis

Interventions: Drug: Placebos
Drug: Estradiol
Drug: Reference

First Posted Date: 2016-12-16

Last Posted Date: 2021-12-01

Lead Sponsor: Alvogen Pine Brook LLC

Target Recruit Count: 535

Registration Number: NCT02995694

Patient Adherence to Premarin Versus Vagifem Therapy After Female Pelvic Reconstructive Surgery

Phase 4

Withdrawn

Conditions: Estrogen
Menopause
Pelvic Floor Disorders
Surgery

Interventions: Drug: Premarin
Drug: Vagifem

First Posted Date: 2016-08-09

Last Posted Date: 2018-05-02

Lead Sponsor: University Hospitals Cleveland Medical Center

Registration Number: NCT02860897

Locations: 🇺🇸
University Hospitals Case Medical Center, Cleveland, Ohio, United States

Estradiol and Fear Extinction in Anorexia Nervosa (AN)

Phase 1

Withdrawn

Conditions: Anorexia Nervosa

Interventions: Drug: Estradiol

First Posted Date: 2016-06-07

Last Posted Date: 2018-08-24

Lead Sponsor: Johns Hopkins University

Registration Number: NCT02792153

Locations: 🇺🇸
Johns Hopkins Hospital, Baltimore, Maryland, United States

Effects of Sex Steroids on the Serotonin System

Phase 4

Conditions: Gender Dysphoria

Interventions: Drug: Cyproterone Acetate
Drug: Testosterone
Drug: Lynestrenol
Drug: Estradiol
Drug: Triptorelin acetate

First Posted Date: 2016-03-22

Last Posted Date: 2018-10-15

Lead Sponsor: Medical University of Vienna

Target Recruit Count: 92

Registration Number: NCT02715232

Locations: 🇦🇹
Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria

Evaluation and Treatment of Tall Statured Girls

Conditions: Constitutional Tall Stature

Interventions: Drug: Estradiol

First Posted Date: 2015-12-23

Last Posted Date: 2016-04-06

Lead Sponsor: Rigshospitalet, Denmark

Target Recruit Count: 304

Registration Number: NCT02638922

The Vaginal Health Trial

Phase 3

Completed

Conditions: Menopause
Atrophy of Vagina
Dyspareunia (Female)

Interventions: Device: Replens
Drug: Vagifem
Other: Placebo gel
Other: Placebo tablet

First Posted Date: 2015-08-05

Last Posted Date: 2018-07-12

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 302

Registration Number: NCT02516202

Locations: 🇺🇸
Kaiser Permanente Washington Health Research Institute, Seattle, Washington, United States
🇺🇸
University of Minnesota, Minneapolis, Minnesota, United States